AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Pacific Biosciences of California, Inc.
Video analysis: PACB
All videosNo video analysis for this stock yet. Request one from our team.
News: PACB
Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know
Pacific Biosciences of California (PACB) closed at $1.27 in the latest trading session, marking a -1.55% move from the prior day.
Pacific Biosciences (PACB) Up 11.6% Since Last Earnings Report: Can It Continue?
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock?
PacBio to Participate in the Morgan Stanley 24ᵗʰ Annual Global Healthcare Conference
MENLO PARK, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 4:50 PM ET in New York, New York.
PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test
PacBio cut its 2026 revenue outlook as weaker instrument demand and a slower SPRQ-Nx transition raised the stakes for clinical adoption.
Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.
On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced positive topline Phase 3 results from INTerpath-001 for intismeran autogene, an individualized neoantigen therapy paired with Keytruda in resected melanoma.
PacBio Cuts Outlook as SPRQ-Nx Transition Slows, Targets 2028 Cash-Flow Positivity
Pacific Biosciences of California NASDAQ: PACB reported second-quarter revenue of $39 million, including $20 million in consumables revenue, $13 million in instrument revenue and $6 million in services revenue, CFO Jim Gibson said during the Canaccord Genuity Growth Conference.
PacBio Q2 Earnings Meet Estimates, Revenues Miss, 2026 Sales View Cut
PACB cuts its 2026 revenue outlook after Q2 sales fall 2%, as consumables and EMEA growth fail to offset weaker instruments and Asia-Pacific.
Pacific Biosciences: It's Only Getting Worse
Pacific Biosciences reported Q2 revenues of $39.01 million, missing estimates and guiding 2026 revenues down, below consensus. Operating and net losses remain sizable, with cash now under $237 million and nearly $645 million in debt outstanding. PACB trades at 2.4x expected 2026 revenues, a steep discount to peers, reflecting weaker financials and growth prospects.
